SCHEMBL18057233

SCHEMBL18057233

CN(C(=O)[C@H](Cc1cc(F)cc(F)c1)NC(=O)NS(=O)(=O)c1ccccc1F)c1ccc2sccc2c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PYGL P06737 2/20 0.35
PER2 O15055 1/20 0.34
CRY1 Q16526 1/20 0.34
CRY2 Q49AN0 1/20 0.34
MAPT P10636 1/20 0.34
KMT2A Q03164 3/20 0.32
LMNA P02545 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
MMP2 P08253 3/20 0.31
MMP8 P22894 3/20 0.31
MMP1 P03956 2/20 0.31
MMP9 P14780 2/20 0.31
KAT6A Q92794 4/20 0.31
POLB P06746 1/20 0.31
PKM P14618 1/20 0.31
MEN1 O00255 2/20 0.30
ALDH1A1 P00352 1/20 0.30
ATM Q13315 1/20 0.30
SLC6A2 P23975 1/20 0.30
SLC6A4 P31645 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18057246 0.93 MMP2 (0.38) PYGLPER2CRY1CRY2MMP2
SCHEMBL18057237 0.92 PER2 (0.35) PYGLPER2CRY1CRY2ALDH1A1
SCHEMBL18057239 0.92 KCNH2 (0.38) PYGLPER2CRY1CRY2MAPT
SCHEMBL18057235 0.92 PYGL (0.33) PYGLPER2CRY1CRY2MAPT
SCHEMBL19999761 0.89 PYGL (0.34) PYGLPER2CRY1CRY2MMP8
SCHEMBL16670640 0.86 ALOX5AP (0.38) PYGLMAPTMMP2MMP8MMP1
SCHEMBL16670643 0.86 ALOX5AP (0.38) PYGLMAPTMMP2MMP8MMP1
SCHEMBL19999758 0.85 PYGL (0.36) PYGLPER2CRY1CRY2MAPT
SCHEMBL19999763 0.85 PYGL (0.37) PYGLPER2CRY1CRY2KMT2A
SCHEMBL18057245 0.84 MMP9 (0.45) PYGLPER2CRY1CRY2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10035760-B2 Inhibitors of human immunodeficiency virus replication VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2018-07-31 US disclosed
US-20160257645-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2016-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160257645-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, POLR1E, POLR1G PYGL 641/4885PER2 3023/4885CRY1 4555/4885
US-10035760-B2 Inhibitors of human immunodeficiency virus replication EIF2AK2, POLR1G, POLR1E PYGL 626/4885PER2 2868/4885CRY1 4474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.